Category - Features

Features

Anixa Biosciences harnessing interactions between tumors and the immune system

Anixa Biosciences (NASDAQ:ANIX) is taking multiple approaches to fighting cancer, developing both a diagnostic and therapeutics, such as a cancer immunotherapy and vaccine, to overcome immuno-suppression. Anixa...

March 3, 2020

Features

Ocugen developing therapies for rare and underserved eye diseases

Ocugen (NASDAQ:OCGN) is taking a multi-pronged approach to ophthalmology with a diversified pipeline that includes a breakthrough modifier gene therapy platform, novel biologics and small molecules, targeting a broad...

February 25, 2020

Features

Genocea Biosciences: for the next generation of immunotherapies, targets matter

Using its unique ATLAS proprietary technology platform, Genocea Biosciences (NASDAQ:GNCA) is developing cancer immunotherapies that direct the body’s own tumor-fighting T-cells to the most therapeutically relevant...

February 18, 2020

Features

Ripple Therapeutics pursues financing for Phase 2 intravitreal implant trial and Epidel platform expansion

Closely-held Ripple Therapeutics, a recent spinout from Interface Biologics, is pursuing a $25-million series A financing to complete a Phase 2 trial of IBE-814 IVT, a dexamethasone prodrug intravitreal implant, and...

February 11, 2020

Features

Stereotaxis focused on next generation robotic innovation in interventional medicine

Stereotaxis’ (NYSE American: STXS) launch in June 2019 of a next generation surgical robotic system, Genesis RMN, solidifies its commitment to innovation and collaboration as a stepping stone to improve patient care...

February 4, 2020

Features

Inagene personalizing pain management with comprehensive genetic test

Closely-held pharmacogenetics company, Inagene Diagnostics, aims to replace the “trial-and-error” approach to pain management with a comprehensive genetic test that helps physicians provide personalized pain management...

January 28, 2020

Features

Liminal BioSciences making headway in strategic transformation

Liminal BioSciences (NASDAQ, TSX:LMNL) is undergoing a significant strategic transformation to simplify its operations, achieve financial stability and focus R&D on small molecule therapeutics. “This is a refresh of...

January 21, 2020

Features

iBio’s transformation driven by FastPharming System, 3D bioprinting materials and proprietary therapeutics

iBio (NYSE American:IBIO) is continuing its transition from a licensing business to a manufacturing services provider and developer of proprietary biologics. Central to the initiative is a new brand for its core...

January 14, 2020

Features

BriaCell breast cancer program ready for partnering

BriaCell Therapeutics (OTCQB:BCTXD; TSXV:BCT) believes its Phase 2 clinical program in advanced breast cancer, which includes an ongoing combination study of its Bria-IMT with immune checkpoint inhibitors such as...

January 7, 2020

Features

Clene Nanomedicine developing first nanotherapeutic for neurodegenerative disease

Closely-held Clene Nanomedicine is developing catalytic drugs to treat neurodegenerative diseases, using its clean surface nanocrystal (CSN) therapeutics platform to increase cellular bioenergy. “We’re the first...

December 17, 2019

Category - Features

Anixa Biosciences harnessing interactions between tumors and the immune system

Ocugen developing therapies for rare and underserved eye diseases

Genocea Biosciences: for the next generation of immunotherapies, targets matter

Ripple Therapeutics pursues financing for Phase 2 intravitreal implant trial and Epidel platform expansion

Stereotaxis focused on next generation robotic innovation in interventional medicine

Inagene personalizing pain management with comprehensive genetic test

Liminal BioSciences making headway in strategic transformation

iBio’s transformation driven by FastPharming System, 3D bioprinting materials and proprietary therapeutics

BriaCell breast cancer program ready for partnering

Clene Nanomedicine developing first nanotherapeutic for neurodegenerative disease

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter